These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24868139)

  • 21. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
    Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
    Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.
    Sudaka A; Susini A; Lo Nigro C; Fischel JL; Toussan N; Formento P; Tonissi F; Lattanzio L; Russi E; Etienne-Grimaldi MC; Merlano M; Milano G
    Invest New Drugs; 2013 Feb; 31(1):59-65. PubMed ID: 22714791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ranibizumab efficiently blocks migration but not proliferation induced by growth factor combinations including VEGF in retinal endothelial cells.
    Deissler HL; Deissler H; Lang GK; Lang GE
    Graefes Arch Clin Exp Ophthalmol; 2013 Oct; 251(10):2345-53. PubMed ID: 23760670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.
    Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL
    Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ranibizumab interacts with the VEGF-A/VEGFR-2 signaling pathway in human RPE cells at different levels.
    Ranjbar M; Brinkmann MP; Tura A; Rudolf M; Miura Y; Grisanti S
    Cytokine; 2016 Jul; 83():210-216. PubMed ID: 27163716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.
    Yang H; Jager MJ; Grossniklaus HE
    Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):2835-42. PubMed ID: 20089875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of ranibizumab on the extracellular matrix production by human Tenon's fibroblast.
    Md Noh SM; Sheikh Abdul Kadir SH; Bannur ZM; Froemming GA; Abdul Hamid Hasani N; Mohd Nawawi H; Crowston JG; Vasudevan S
    Exp Eye Res; 2014 Oct; 127():236-42. PubMed ID: 25139730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells.
    Spitzer MS; Wallenfels-Thilo B; Sierra A; Yoeruek E; Peters S; Henke-Fahle S; Bartz-Schmidt KU; Szurman P;
    Br J Ophthalmol; 2006 Oct; 90(10):1316-21. PubMed ID: 16723358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization.
    Puddu A; Sanguineti R; Durante A; Nicolò M; Viviani GL
    Mol Vis; 2012; 18():2509-17. PubMed ID: 23112566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VEGF but not PlGF disturbs the barrier of retinal endothelial cells.
    Deissler HL; Deissler H; Lang GK; Lang GE
    Exp Eye Res; 2013 Oct; 115():162-71. PubMed ID: 23891860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
    Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
    Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
    Deissler HL; Deissler H; Lang GE
    Br J Ophthalmol; 2012 Jul; 96(7):1023-8. PubMed ID: 22539748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth.
    El Filali M; Homminga I; Maat W; van der Velden PA; Jager MJ
    Mol Vis; 2008 Sep; 14():1752-9. PubMed ID: 18836566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1.
    Lee TH; Seng S; Sekine M; Hinton C; Fu Y; Avraham HK; Avraham S
    PLoS Med; 2007 Jun; 4(6):e186. PubMed ID: 17550303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
    Melanoma Res; 2006 Oct; 16(5):405-11. PubMed ID: 17013089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
    Klettner A; Recber M; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.
    Klettner AK; Kruse ML; Meyer T; Wesch D; Kabelitz D; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1601-8. PubMed ID: 19597740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas.
    Baumgarten P; Brokinkel B; Zinke J; Zachskorn C; Ebel H; Albert FK; Stummer W; Plate KH; Harter PN; Hasselblatt M; Mittelbronn M
    Histol Histopathol; 2013 Sep; 28(9):1157-66. PubMed ID: 23475388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt.
    Byeon SH; Lee SC; Choi SH; Lee HK; Lee JH; Chu YK; Kwon OW
    Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1190-7. PubMed ID: 19834034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.